LENZ Therapeutics, Inc.

Historical 13F Holders

Symbol
LENZ
CUSIP
52635N103
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Filings

13D/G Filers

Investors who own more than 5% of a class must file a Schedule 13D or 13G. Each filer's latest filing for 52635N103 since 12/18/2024, largest first.

Filer % of Class Filed
RA Capital Management, L.P. 13D/A
13.6% 11/7/2025
Event 11/5/2025
BlackRock, Inc. 13G 5.8% 4/27/2026
Event 3/31/2026
FMR LLC 13G/A
5.7% 9/8/2026
Event 8/31/2026
Millennium Management LLC 13G
5.1% 6/26/2026
Event 6/23/2026
Squarepoint Ops LLC 13G
5.1% 4/8/2026
Event 4/1/2026
Under 5%, checked the "5 percent or less" box, or amended by a later filing (4)
Point72 Asset Management, L.P. 13G/A
4.8% 11/14/2025
Event 9/30/2025
Paradigm Biocapital Advisors LP 13G/A
3.8% 11/14/2025
Event 9/30/2025
Versant Venture Capital VI, L.P. 13D/A
3.4% 11/10/2025
Event 11/5/2025
Ridgeback Capital Investments L.P. 13G/A
0% 2/17/2026
Event 12/31/2025

13F Holders by Quarter

Period Filings Shares, Excl. Options Value, Excl. Options
2026 Q3 2 1.15 k $4.40 k
2026 Q2 152 34.7 M $198 M
2026 Q1 153 33.1 M $303 M
2025 Q4 170 35.1 M $562 M
2025 Q3 173 29.2 M $1.36 B
2025 Q2 122 24.8 M $726 M
2025 Q1 106 21.1 M $542 M
2024 Q4 96 19.9 M $572 M
2024 Q3 80 18.7 M $445 M
2024 Q2 68 19.0 M $328 M
2024 Q1 60 16.3 M $363 M